All In MedTech

FDA Clearance Tracker · P930016-S014

VISX STAR EXCIMER LASER SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 6, 2001 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 6, 2001

Approved

Time to decision

155 days

Received Jun 4, 2001. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P930016-S014
Device name
VISX STAR EXCIMER LASER SYSTEM
Applicant location
Milpitas, CA
Received
Jun 4, 2001
Decided
Nov 6, 2001
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P930016

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE VISX STAR S2 AND S3 EXCIMER LASER SYSTEMS. THE DEVICES ARE INDICATED FOR LASER IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS: 1) IN PATIENTS WITH DOCUMENTED EVIDENCE OF A CHANGE IN MANIFEST REFRACTION OF NO MORE THAN 0.5 D (IN BOTH CYLINDER AND SPHERE COMPONENTS) FOR AT LEAST ONE YEAR PRIOR TO THE DATE OF PRE-OPERATIVE EXAMINATION; AND 2) IN PATIENTS 21 YEARS OF AGE OF OLDER IN TREATMENTS FOR THE REDUCTION OR ELIMINATION OF NATURALLY OCCURRING MIXED ASTIGMATISM WHERE THE MAGNITUDE OF CYLINDER (<=6.0 D AT THE SPECTACLE PLANE) IS GREATER THAN THE MAGNITUDE OF SPHERE AND THE CYLINDER AND SPHERE HAVE OPPOSITE SIGNS.

Source documents

Other decisions for Amo Manufacturing USA, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.